Find an expert

I am a medicinal chemist and postdoctoral research fellow at the University of Queensland, Australia, where I obtained my BSc (Hons) with a major in organic chemistry in 2011. Following this, I worked at the Institute for Future Environments and later the Centre for Tropical Crops and Biocommodities at QUT, where I gained experience in analytical chemistry, as well as molecular biology and genetics. In 2015, I returned to UQ to begin my PhD in the design and synthesis of novel antifungals targeting invasive infection under the supervision of Prof. Craig Williams and Prof. Luke Guddat, which I completed in 2019. Since this time I have worked at the School of Chemistry and Molecular Biosciences as a Postdoctoral Research Fellow under the supervision of Prof. Craig Williams, Prof. Avril Robertson, and now Prof. James De Voss. Broadly, my research interests lie in the pursuit of drug design and development campaigns addressing difficult or under-researched clinical concerns, and in particular, the use of novel bioisosteric approaches to improve drugability and drug efficacy.

More recently, I have developed an interest in Australian mushroom species. Very little recorded knowledge on our endemic mushrooms species exists. My research in this space seeks to characterise the genetic and molecular features of Australian wood rot mushrooms, which are critical players in maintaining and restoring the health of our unique forests ecosystems. With this information we aim to better understand our fungal biodiversity and the ecological roles they play, and to explore their potential as a platform for the identification of new drug molecules.

Plant viruses and horticultural crop improvement

Dr Dietzgen is internationally recognised for his work on plant virus characterisation, detection and engineered resistance. Before joining UQ, Dr Dietzgen was a Science Leader in Agri-Science in the Queensland Department of Employment, Economic Development and Innovation. He previously held research positions at the University of Adelaide, University of California, Cornell University and University of Kentucky. Dr Dietzgen’s research interests are in molecular virus-plant-insect interactions, virus biodiversity and evolution, and disease resistance mechanisms. His focus is on the biology of RNA viruses in the family Rhabdoviridae and the molecular protein interactions of plant-adapted rhabdoviruses and tospoviruses. He has published extensively on plant virus characterisation and genetic variability, RNAi- mediated virus resistance and diagnostic technologies with 20 review articles and book chapters and over 65 peer-reviewed publications.

A/Prof Landsberg's undergraudate and Honours studies, majoring in Chemistry, were completed at Central Queensland University and the CSIRO (JM Rendel laboratories) before he moved to the University of Queensland to study a PhD in Biochemistry (awarded 2003). He then moved to a postdoctoral position at the Institute for Molecular Bioscience, spending time as a Visiting Scientist at Harvard Medical School (2008) and securing promotion to Senior Research Officer upon his return to IMB in 2009. He additioanlly spent time as a Visiting Scientist at the Victor Chang Cardiac Research Institute in 2010 and 2011.

In 2016, he joined UQ's School of Chemistry and Molecular Biosciences as a Group Leader in Cryo-EM and Macromolecular Structure and Senior Lecturer in Biochemistry and Biophysics, where he was promoted to Associate Professor in 2019. He has secured >$13.5M in competitive research funding since 2012, including major grants from the Australian Research Council and National Health and Medical Research Council. He his research has been presented at over 70 national and international conferences and research institutions.

Soumyalekshmi Nair has a degree in Veterinary and Animal Sciences (2009) and a Master of Veterinary Science in Animal Biotechnology (2011) from India. She completed her PhD in 2021 from the Faculty of Medicine, the University of Queensland. In her PhD she investigated the role of extracellular vesicles in gestational diabetes mellitus which involves developing extracellular vesicle -based biomarker for the early screening of pregnant women as well as therapeutic targets for the treatment of women with gestational diabetes. She was awarded the Research Training Scholarship from the University of Queensland and received prestigious awards from the Society of Reproductive Investigation and Australian and New Zealand Society for Extracellular Vesicles. Currently she is a Postdoctoral Research Fellow at the Exosome Biology Lab, UQ Centre for Clinical Research (UQCCR). Her research interest is understanding the molecular mechanism by which extracellular vesicles can regulate the key signalling pathways in diseases such as obesity, diabetes, and ovarian cancer, with a focus on translating this knowledge into clinical utility. She has several key publications in the field including research articles and reviews and presented at major national and international conferences. She is passionate about supporting women in science and enhancing community engagement in Science, Technology, Engineering and Mathematics (STEM).

Dr Melanie Robitaille is a Senior Post-Doctoral Researcher working with the Calcium Signalling in Therapeutics Team (CaSTT) in the School of Pharmacy. This team specializes in the development and application of novel methodologies and cellular assays in drug discovery, including the use of genetically encoded indicator for high-content imaging in live cells.

Her interests are to elucidate how calcium signals are remodelled in disease states, to identify calcium transporters as new therapeutic targets and to develop molecular and cellular screening tools to be used in drug development programs. She has an established profile in cellular and molecular biology, with high expertise in plasmid cloning, lentiviral transduction and the use of CRISPR/Cas9 to modulate gene expression.

I am Professor, NHMRC Investigator Fellow (EL2) and group leader (Exosome Biology Laboratory) at UQ Centre for Clinical Research. I am nationally and internationally (>20 invitations to international meetings in the last 5 years) acknowledged key opinion leader on Extracellular Vesicle (rated 3th worldwide (Top 0.015%) and 1st in Australia in expertise for “Extracellular Vesicles and Exosomes” on Expertscape) and biomarker discovery (140 publications, and >8000 citations in the last 7 year). I have made a major conceptual contribution to EV biology with diagnostic and therapeutic implications. In the last 8 years, my primary research and commercialisation activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications. In Academia, I have pursued these objectives through the development and leadership of clinical translation research teams and facilities, both in Australia and overseas. For example, I had a leadership role in established the Centre for Clinical Diagnostics (CCD). Within the UQCCR, I established an exosome research team to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Much of our effort in this field of endeavour has involved optimising isolation methods for extracellular vesicles and their analytical analysis - including the use of protein solution array (e.g. Luminex), mass spectrometry profiling (using MS/MS SWATH) and more recently miRNA analysis.

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

My research interests are centred around the structure and function of venom and silk polypeptides produced by arthropods, and their use in biotechnology and medicine. I am a Postdoctoral Fellow in the King laboratory in the Institute for Molecular Bioscience, the University of Queensland, Australia. Currently, I am investigating the composition, function and evolution of neglected insect venoms produced by assassin bugs (Hemiptera: Reduviidae), robber flies (Diptera: Asilidae) and nettle caterpillars (Lepidoptera: Limacodidae).